FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183193407> ?p ?o ?g. }

• W2183193407 endingPage "56" @default.
• W2183193407 startingPage "2745" @default.
• W2183193407 abstract "Neoangiogenesis is assumed to play an important role in the progression, metastasis and prognosis of a wide variety of tumors. To get insights into the molecular-genetic pathways and the biological role of angiogenesis in urothelial carcinogenesis, we analyzed comparatively the expression of the mRNA of the vascular endothelial growth factor (VEGF) and of the angiopoietins-1 and -2 (Ang-1 and Ang-2) in 71 transitional cell carcinomas (TCC) of the urinary bladder in relation to the tumor grades and stages, and referring to epidemiological risk factors. Using real-time quantitative reverse transcription-polymerase chain reaction, low-stage superficial TCC expressed VEGF and Ang-2 mRNA at a significantly higher level than high-stage muscle invasive carcinomas, and low-grade TCC at an insignificantly higher level than high-grade tumors. The activity of both angiogenic factors was found to be significantly correlated. Conversely, Ang-1 mRNA was expressed at a 3-fold significantly lower level in low-grade, low-stage compared to high-grade, high-stage TCC. A significantly 3- and 2-fold respectively, drop of the VEGF and Ang-2 mRNA expression in conjunction with a 2-fold significantly higher expression of Ang-1 mRNA in the group of grade 2 TCC when infiltrating the muscle layer may represent a crucial event during urothelial carcinogenesis, and possibly indicates an important step in promoting the conversion of bladder cancer from a low to a high malignancy in this subset of carcinomas. By immunhistochemistry, high-grade, high-stage carcinomas less frequently displayed areas with a strong reactivity for the VEGF protein ('hot spots) than low-grade, low-stage TCC, paralleling the expression of the mRNA. The expression patterns observed are compatible with a reduced vascular destabilization and decreased formation of new blood vessels in advanced TCC, suggesting a balance between vessel regression and vascular growth, with a less pronounced vascular remodeling during late phases of urothelial carcinogenesis. Analyzing the effect of life-style bladder cancer risk factors, habitual smoking and coffee consumption was not observed to substantially alter the expression of the angiogenic mediators, except for weakly elevated levels of VEGF and Ang-2 mRNA in TCC of strong smokers and a borderline significantly decreased VEGF mRNA expression associated with heavy coffee consumption. Certain hazardous occupational exposures (polycyclic hydrocarbons, paints and lacquer, stone dust) may play a role in modulating tumor angiogenesis. The current data indicate that the signaling molecular-genetic pathways underlying vascular remodeling are involved in the progression of urinary bladder cancer to a more malignant and aggressive behaviour." @default.
• W2183193407 created "2016-06-24" @default.
• W2183193407 creator A5037280809 @default.
• W2183193407 creator A5060504547 @default.
• W2183193407 creator A5070094252 @default.
• W2183193407 creator A5071176989 @default.
• W2183193407 creator A5071424411 @default.
• W2183193407 creator A5071867387 @default.
• W2183193407 creator A5088448998 @default.
• W2183193407 date "2004-11-03" @default.
• W2183193407 modified "2023-10-05" @default.
• W2183193407 title "Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression." @default.
• W2183193407 cites W1493048246 @default.
• W2183193407 cites W1531748014 @default.
• W2183193407 cites W1573363574 @default.
• W2183193407 cites W1578666381 @default.
• W2183193407 cites W1603098046 @default.
• W2183193407 cites W1607187127 @default.
• W2183193407 cites W1677040759 @default.
• W2183193407 cites W1783580437 @default.
• W2183193407 cites W1998143920 @default.
• W2183193407 cites W2012255417 @default.
• W2183193407 cites W2013990053 @default.
• W2183193407 cites W2034822725 @default.
• W2183193407 cites W2035907364 @default.
• W2183193407 cites W2038847166 @default.
• W2183193407 cites W2046305550 @default.
• W2183193407 cites W2048306047 @default.
• W2183193407 cites W2050740674 @default.
• W2183193407 cites W2054203847 @default.
• W2183193407 cites W2054331246 @default.
• W2183193407 cites W2064739543 @default.
• W2183193407 cites W2066888615 @default.
• W2183193407 cites W2100007292 @default.
• W2183193407 cites W2110661995 @default.
• W2183193407 cites W2113920157 @default.
• W2183193407 cites W2134175200 @default.
• W2183193407 cites W2136989771 @default.
• W2183193407 cites W2142173484 @default.
• W2183193407 cites W2146134896 @default.
• W2183193407 cites W2148684437 @default.
• W2183193407 cites W2152215024 @default.
• W2183193407 cites W2156556767 @default.
• W2183193407 cites W2161878633 @default.
• W2183193407 cites W2164724870 @default.
• W2183193407 cites W2169256297 @default.
• W2183193407 cites W2169497014 @default.
• W2183193407 cites W2170770755 @default.
• W2183193407 cites W2280004510 @default.
• W2183193407 cites W2285543173 @default.
• W2183193407 cites W3150425063 @default.
• W2183193407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15517881" @default.
• W2183193407 hasPublicationYear "2004" @default.
• W2183193407 type Work @default.
• W2183193407 sameAs 2183193407 @default.
• W2183193407 citedByCount "8" @default.
• W2183193407 countsByYear W21831934072014 @default.
• W2183193407 countsByYear W21831934072015 @default.
• W2183193407 countsByYear W21831934072016 @default.
• W2183193407 countsByYear W21831934072020 @default.
• W2183193407 crossrefType "journal-article" @default.
• W2183193407 hasAuthorship W2183193407A5037280809 @default.
• W2183193407 hasAuthorship W2183193407A5060504547 @default.
• W2183193407 hasAuthorship W2183193407A5070094252 @default.
• W2183193407 hasAuthorship W2183193407A5071176989 @default.
• W2183193407 hasAuthorship W2183193407A5071424411 @default.
• W2183193407 hasAuthorship W2183193407A5071867387 @default.
• W2183193407 hasAuthorship W2183193407A5088448998 @default.
• W2183193407 hasConcept C121608353 @default.
• W2183193407 hasConcept C126322002 @default.
• W2183193407 hasConcept C142724271 @default.
• W2183193407 hasConcept C146357865 @default.
• W2183193407 hasConcept C151730666 @default.
• W2183193407 hasConcept C167734588 @default.
• W2183193407 hasConcept C2777025900 @default.
• W2183193407 hasConcept C2777540882 @default.
• W2183193407 hasConcept C2778065480 @default.
• W2183193407 hasConcept C2779013556 @default.
• W2183193407 hasConcept C2779256057 @default.
• W2183193407 hasConcept C2779399171 @default.
• W2183193407 hasConcept C2779762690 @default.
• W2183193407 hasConcept C2780352672 @default.
• W2183193407 hasConcept C2780394083 @default.
• W2183193407 hasConcept C502942594 @default.
• W2183193407 hasConcept C555283112 @default.
• W2183193407 hasConcept C71924100 @default.
• W2183193407 hasConcept C86803240 @default.
• W2183193407 hasConceptScore W2183193407C121608353 @default.
• W2183193407 hasConceptScore W2183193407C126322002 @default.
• W2183193407 hasConceptScore W2183193407C142724271 @default.
• W2183193407 hasConceptScore W2183193407C146357865 @default.
• W2183193407 hasConceptScore W2183193407C151730666 @default.
• W2183193407 hasConceptScore W2183193407C167734588 @default.
• W2183193407 hasConceptScore W2183193407C2777025900 @default.
• W2183193407 hasConceptScore W2183193407C2777540882 @default.
• W2183193407 hasConceptScore W2183193407C2778065480 @default.
• W2183193407 hasConceptScore W2183193407C2779013556 @default.
• W2183193407 hasConceptScore W2183193407C2779256057 @default.

• next